Related references
Note: Only part of the references are listed.Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
Murdo Ferguson et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Immunogenicity and Safety of the Influenza A/H1N1 2009 Inactivated Split-Virus Vaccine in Young and Older Adults: MF59-Adjuvanted Vaccine versus Nonadjuvanted Vaccine
Hee Jin Cheong et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
MF59 adjuvant: the best insurance against influenza strain diversity
Derek T. O'Hagan et al.
EXPERT REVIEW OF VACCINES (2011)
Influenza vaccine immunology
Philip R. Dormitzer et al.
IMMUNOLOGICAL REVIEWS (2011)
Avian-Type Receptor-Binding Ability Can Increase Influenza Virus Pathogenicity in Macaques
Tokiko Watanabe et al.
JOURNAL OF VIROLOGY (2011)
MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk
Paolo Durando et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
Filippo Ansaldi et al.
VACCINE (2010)
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
G Del Giudice et al.
VACCINE (2006)
Immunogenicity and protective efficacy of influenza vaccination
C Hannoun et al.
VIRUS RESEARCH (2004)
Share Paper
